{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:49:25Z","timestamp":1785919765880,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.radonc.2026.111388","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:20:45Z","timestamp":1769127645000},"page":"111388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data"],"prefix":"10.1016","volume":"217","author":[{"given":"Philippa","family":"Johnstone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9718-9596","authenticated-orcid":false,"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2771-8827","authenticated-orcid":false,"given":"Surender","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-046X","authenticated-orcid":false,"given":"Haris","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0900-5815","authenticated-orcid":false,"given":"Michael","family":"MacManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111388_b0005","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1200\/jco.2004.22.90140.6521","article-title":"Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone","volume":"22","author":"Petersen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111388_b0010","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for Stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111388_b0015","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0889-8588(05)70469-X","article-title":"Overview of treatment of localized low-grade lymphomas","volume":"11","author":"Mac Manus","year":"1997","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.radonc.2026.111388_b0020","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ijrobp.2019.06.447","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma: an update of a population-based study","volume":"105","author":"Lo","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111388_b0025","article-title":"Maximum disease diameter is associated with outcomes in stage II follicular lymphoma treated with radiation therapy alone","volume":"49","author":"Xu","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111388_b0030","article-title":"Treat in brief: early relapsing follicular lymphoma","author":"Barr","year":"2020","journal-title":"ASH Clin News"},{"key":"10.1016\/j.radonc.2026.111388_b0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111388_b0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111388_b0045","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2019.03.004","article-title":"Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: a collaborative study on behalf of ILROG","volume":"104","author":"Binkley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111388_b0050","article-title":"Treatment of follicular lymphoma with a focus on radiotherapy","volume":"2","author":"Tan","year":"2024","journal-title":"R College Radiol Open"},{"key":"10.1016\/j.radonc.2026.111388_b0055","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111388_b0060","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111388_b0065","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1182\/blood-2018-99-114097","article-title":"Outcomes of stage I and II follicular lymphoma in the era of 18F-FDG PET-CT staging: an international collaborative study from the Australian lymphoma alliance","volume":"132","author":"Tobin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2026.111388_b0070","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111388_b0075","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111388_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105468","article-title":"Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma","volume":"110","author":"MacManus","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.radonc.2026.111388_b0085","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology: B Cell Lymphomas [Internet]. NCCN. 2024 [cited 24 AD 11];Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"10.1016\/j.radonc.2026.111388_b0090","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/imj.14113","article-title":"Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma","volume":"49","author":"Trotman","year":"2019","journal-title":"Intern Med J"},{"key":"10.1016\/j.radonc.2026.111388_b0095","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70002","article-title":"An economic evaluation of the TROG 99.03 trial: systemic therapy after radiotherapy in early-stage follicular lymphoma","volume":"6","author":"Erku","year":"2025","journal-title":"EJHaem"},{"key":"10.1016\/j.radonc.2026.111388_b0100","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2026.111388_b0105","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111388_b0110","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111388_b0115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/cancers16030649","article-title":"Long-term results of IFRT vs. ISRT in infradiaphragmal fields in aggressive non-hodgkins\u2019s lymphoma patients-a single centre experience","volume":"16","author":"Galunic Bilic","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2026.111388_b0120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111388_b0125","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.16872","article-title":"The investigation and management of follicular lymphoma","volume":"191","author":"McNamara","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.radonc.2026.111388_b0130","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","article-title":"Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study","volume":"94","author":"Ruella","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111388_b0135","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","article-title":"Rituximab with involved field irradiation for early\u2010stage nodal follicular lymphoma","volume":"2","author":"Herfarth","year":"2018","journal-title":"HemaSphere"},{"key":"10.1016\/j.radonc.2026.111388_b0140","unstructured":"Anderson Cancer Centre MD. Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma (Clinicaltrials.gov ID NCT01473628)."},{"key":"10.1016\/j.radonc.2026.111388_b0145","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mds433","article-title":"Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy","volume":"24","author":"Bains","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111388_b0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-022-00620-w","article-title":"Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma","volume":"12","author":"Sha","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.radonc.2026.111388_b0155","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.radonc.2026.111388_b0160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-021-00574-5","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018","volume":"11","author":"Dinnessen","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.radonc.2026.111388_b0165","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1007\/s00277-024-06022-1","article-title":"Is radiotherapy still the optimal initial choice for patients with early-stage low-grade follicular lymphoma in the modern era? A population-based study","volume":"103","author":"Zheng","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.radonc.2026.111388_b0170","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/cam4.5139","article-title":"Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality","volume":"12","author":"Parsons","year":"2023","journal-title":"Cancer Med"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:18:17Z","timestamp":1785917897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026000265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"alternative-id":["S0167814026000265"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111388","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111388"}}